

PHARMACEUTICAL 2023



INTEGRATED BIOPHARMA INC Rank 74 of 446







RealRate

PHARMACEUTICAL 2023



INTEGRATED BIOPHARMA INC Rank 74 of 446

The relative strengths and weaknesses of INTEGRATED BIOPHARMA INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of INTEGRATED BIOPHARMA INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 297% points. The greatest weakness of INTEGRATED BIOPHARMA INC is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 298% points.

The company's Economic Capital Ratio, given in the ranking table, is 224%, being 181% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	16,626
Cost of Goods Sold	49,694
Intangible Assets	0
Liabilities, Current	5,263
Liabilities, Non-Current	1,412
Other Assets	6,714
Other Compr. Net Income	0
Other Expenses	-1,241
Other Liabilities	0
Other Net Income	-148
Other Revenues	56,246
Property and Equipment	1,910
Research and Development	0
Selling, General and Administrative Expense	3,807

Output Variable	Value in 1000 USD
Assets	25,250
Liabilities	6,675
Expenses	52,260
Revenues	56,246
Stockholders Equity	18,575
Net Income	3,838
Comprehensive Net Income	3,838
Economic Capital Ratio	224%

